Overview

Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy

Status:
Completed
Trial end date:
1996-08-01
Target enrollment:
Participant gender:
Summary
OBJECTIVES: I. Assess the efficacy of 3,4-diaminopyridine in patients with stable chronic demyelinating polyneuropathy.
Phase:
Phase 3
Details
Lead Sponsor:
National Center for Research Resources (NCRR)
Collaborator:
Mayo Clinic
Treatments:
3,4-diaminopyridine